Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Crit Care ; 73: 154182, 2023 02.
Article in English | MEDLINE | ID: mdl-36368174

ABSTRACT

BACKGROUND: In a multicultural society, the impact of language proficiency and interpreter use on critical care patient outcomes is unknown. OBJECTIVE: To investigate the relationship between English language preference, requirement for an interpreter and in-hospital mortality amongst non-elective intensive care unit (ICU) patients. METHOD: Adult patients admitted to all 23 public ICUs within the state of Victoria, Australia from July 2007 to June 2018, were extracted from The Australian New Zealand Intensive Care Society Adult Patient Database. De-identified patient data was matched using probabilistic methods and statistical linkage keys to the Victorian Admitted Episodes Database. Patients were classified into one of three groups: 'English preferred', 'English not preferred' and 'Interpreter required'. RESULTS: 126,891 ICU admissions were analysed, of whom 3394 (3%) were in the 'English not preferred' group and 6355 (5%) in the 'Interpreter required' group. Compared to the 'English preferred', both the 'English not preferred' and 'Interpreter required' groups were older, had more co-morbidities and higher severity of illness scores. In-hospital mortality was 13.1% in the 'English preferred' group, 19.6% in the 'English not preferred' group and 16.7% in the 'Interpreter required' group. However, after adjusting for sex, severity of illness and socio-economic status, the 'English not preferred' group remained with a higher risk adjusted mortality (OR 1.21, 95%CI 1.07-1.36, P = 0.002), whereas the 'Interpreter required' group had a lower adjusted risk of mortality (OR 0.81, 95%CI 0.74-0.89, P < 0.001). CONCLUSION: Being identified as having a requirement for an interpreter was associated with improved outcomes for adults admitted to public hospital ICUs in Victoria. Interpreter services should be more readily available in the hospital setting. It is recommended that patients, family members and clinicians actively use interpreter services when English is not the preferred language of an ICU patient.


Subject(s)
Communication Barriers , Language , Adult , Humans , Hospitals, Public , Critical Care , Victoria
2.
Med J Aust ; 215(11): 513-517, 2021 12 13.
Article in English | MEDLINE | ID: mdl-34642941

ABSTRACT

OBJECTIVES: To describe the short term ability of Australian intensive care units (ICUs) to increase capacity in response to heightened demand caused by the COVID-19 pandemic. DESIGN: Survey of ICU directors or delegated senior clinicians (disseminated 30 August 2021), supplemented by Australian and New Zealand Intensive Care Society (ANZICS) registry data. SETTING: All 194 public and private Australian ICUs. MAIN OUTCOME MEASURES: Numbers of currently available and potentially available ICU beds in case of a surge; available levels of ICU-relevant equipment and staff. RESULTS: All 194 ICUs responded to the survey. The total number of currently open staffed ICU beds was 2183. This was 195 fewer (8.2%) than in 2020; the decline was greater for rural/regional (18%) and private ICUs (18%). The reported maximal ICU bed capacity (5623) included 813 additional physical ICU bed spaces and 2627 in surge areas outside ICUs. The number of available ventilators (7196) exceeded the maximum number of ICU beds. The reported number of available additional nursing staff would facilitate the immediate opening of 383 additional physical ICU beds (47%), but not the additional bed spaces outside ICUs. CONCLUSIONS: The number of currently available staffed ICU beds is lower than in 2020. Equipment shortfalls have been remediated, with sufficient ventilators to equip every ICU bed. ICU capacity can be increased in response to demand, but is constrained by the availability of appropriately trained staff. Fewer than half the potentially additional physical ICU beds could be opened with currently available staff numbers while maintaining pre-pandemic models of care.


Subject(s)
COVID-19/therapy , Hospital Bed Capacity , Intensive Care Units/organization & administration , Australia/epidemiology , COVID-19/epidemiology , Equipment and Supplies, Hospital/statistics & numerical data , Equipment and Supplies, Hospital/supply & distribution , Humans , Intensive Care Units/statistics & numerical data , New Zealand/epidemiology , Pandemics/prevention & control , Registries/statistics & numerical data
3.
Med J Aust ; 212(10): 463-467, 2020 06.
Article in English | MEDLINE | ID: mdl-32306408

ABSTRACT

OBJECTIVES: To assess the capacity of intensive care units (ICUs) in Australia to respond to the expected increase in demand associated with COVID-19. DESIGN: Analysis of Australian and New Zealand Intensive Care Society (ANZICS) registry data, supplemented by an ICU surge capability survey and veterinary facilities survey (both March 2020). SETTINGS: All Australian ICUs and veterinary facilities. MAIN OUTCOME MEASURES: Baseline numbers of ICU beds, ventilators, dialysis machines, extracorporeal membrane oxygenation machines, intravenous infusion pumps, and staff (senior medical staff, registered nurses); incremental capability to increase capacity (surge) by increasing ICU bed numbers; ventilator-to-bed ratios; number of ventilators in veterinary facilities. RESULTS: The 191 ICUs in Australia provide 2378 intensive care beds during baseline activity (9.3 ICU beds per 100 000 population). Of the 175 ICUs that responded to the surge survey (with 2228 intensive care beds), a maximal surge would add an additional 4258 intensive care beds (191% increase) and 2631 invasive ventilators (120% increase). This surge would require additional staffing of as many as 4092 senior doctors (245% increase over baseline) and 42 720 registered ICU nurses (269% increase over baseline). An additional 188 ventilators are available in veterinary facilities, including 179 human model ventilators. CONCLUSIONS: The directors of Australian ICUs report that intensive care bed capacity could be near tripled in response to the expected increase in demand caused by COVID-19. But maximal surge in bed numbers could be hampered by a shortfall in invasive ventilators and would also require a large increase in clinician and nursing staff numbers.


Subject(s)
Coronavirus Infections/epidemiology , Hospital Bed Capacity , Intensive Care Units/supply & distribution , Pneumonia, Viral/epidemiology , Surge Capacity/trends , Ventilators, Mechanical/supply & distribution , Australia/epidemiology , Betacoronavirus , COVID-19 , Coronavirus Infections/therapy , Coronavirus Infections/virology , Humans , Pandemics , Pneumonia, Viral/therapy , Pneumonia, Viral/virology , SARS-CoV-2
4.
J Neuropathol Exp Neurol ; 62(4): 398-411, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12722832

ABSTRACT

Schwann cell death is a developmentally regulated phenomenon and is also induced after peripheral nerve axotomy in neonatal rodents. In this study, we explored whether ligand-induced activation of the low-affinity neurotrophin receptor (p75(NTR)) is responsible for inducing Schwann cell death in vivo. Administration of exogenous nerve growth factor (NGF) to the axotomized nerve site in wild-type animals resulted in a 2.6-fold increase in Schwann cell apoptosis in the distal nerve stumps compared to axotomy alone. No increase in apoptosis, above baseline levels, was seen in p75(NTR)-mutant mice either with or without NGF When anti-NGF antibodies were administered to the site of the peripheral nerve lesion in wild-type mice there was a reduction in the percentage of Schwann cell apoptosis to levels seen in both the quiescent state and in the axotomized nerves of the p75(NTR)-mutant mice. These results demonstrate that apoptosis of Schwann cells in axotomized peripheral nerve is mediated predominantly through p75(NTR) signaling and initiated via endogenously produced NGF.


Subject(s)
Apoptosis/genetics , Nerve Growth Factor/metabolism , Peripheral Nervous System Diseases/metabolism , Receptors, Nerve Growth Factor/metabolism , Schwann Cells/metabolism , Sciatic Nerve/injuries , Sciatic Neuropathy/metabolism , Animals , Animals, Newborn , Apoptosis/drug effects , Axons/metabolism , Axons/pathology , Axons/ultrastructure , Axotomy , Chemotaxis, Leukocyte/drug effects , Chemotaxis, Leukocyte/genetics , Immunohistochemistry , Mice , Mice, Inbred BALB C , Mice, Mutant Strains , Microscopy, Electron , Mutation/genetics , Nerve Growth Factor/antagonists & inhibitors , Peripheral Nervous System Diseases/genetics , Peripheral Nervous System Diseases/physiopathology , Receptor, Nerve Growth Factor , Receptors, Nerve Growth Factor/drug effects , Receptors, Nerve Growth Factor/genetics , S100 Proteins/metabolism , Schwann Cells/pathology , Schwann Cells/ultrastructure , Sciatic Nerve/growth & development , Sciatic Nerve/metabolism , Sciatic Neuropathy/genetics , Sciatic Neuropathy/physiopathology , Signal Transduction/genetics
SELECTION OF CITATIONS
SEARCH DETAIL